1968 related articles for article (PubMed ID: 17704786)
21. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.
Yamazaki T; Hannani D; Poirier-Colame V; Ladoire S; Locher C; Sistigu A; Prada N; Adjemian S; Catani JP; Freudenberg M; Galanos C; André F; Kroemer G; Zitvogel L
Cell Death Differ; 2014 Jan; 21(1):69-78. PubMed ID: 23811849
[TBL] [Abstract][Full Text] [Related]
22. TLR4 signaling in cancer cells promotes chemoattraction of immature dendritic cells via autocrine CCL20.
Wang L; Liu Q; Sun Q; Zhang C; Chen T; Cao X
Biochem Biophys Res Commun; 2008 Feb; 366(3):852-6. PubMed ID: 18083111
[TBL] [Abstract][Full Text] [Related]
23. Toll-like receptor-dependent activation of antigen-presenting cells affects adaptive immunity to Helicobacter pylori.
Rad R; Brenner L; Krug A; Voland P; Mages J; Lang R; Schwendy S; Reindl W; Dossumbekova A; Ballhorn W; Wagner H; Schmid RM; Bauer S; Prinz C
Gastroenterology; 2007 Jul; 133(1):150-163.e3. PubMed ID: 17631139
[TBL] [Abstract][Full Text] [Related]
24. Partial role of TLR4 as a receptor responding to damage-associated molecular pattern.
Lee KM; Seong SY
Immunol Lett; 2009 Jun; 125(1):31-9. PubMed ID: 19501120
[TBL] [Abstract][Full Text] [Related]
25. Macrophage inflammatory protein derivative ECI301 enhances the alarmin-associated abscopal benefits of tumor radiotherapy.
Kanegasaki S; Matsushima K; Shiraishi K; Nakagawa K; Tsuchiya T
Cancer Res; 2014 Sep; 74(18):5070-8. PubMed ID: 25038226
[TBL] [Abstract][Full Text] [Related]
26. The alarmin cytokine, high mobility group box 1, is produced by viable cardiomyocytes and mediates the lipopolysaccharide-induced myocardial dysfunction via a TLR4/phosphatidylinositol 3-kinase gamma pathway.
Xu H; Su Z; Wu J; Yang M; Penninger JM; Martin CM; Kvietys PR; Rui T
J Immunol; 2010 Feb; 184(3):1492-8. PubMed ID: 20028656
[TBL] [Abstract][Full Text] [Related]
27. Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling.
Wang S; Schmaderer C; Kiss E; Schmidt C; Bonrouhi M; Porubsky S; Gretz N; Schaefer L; Kirschning CJ; Popovic ZV; Gröne HJ
Dis Model Mech; 2010; 3(1-2):92-103. PubMed ID: 20038715
[TBL] [Abstract][Full Text] [Related]
28. Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis.
Lee CH; Wu CL; Shiau AL
Clin Cancer Res; 2008 Mar; 14(6):1905-12. PubMed ID: 18347194
[TBL] [Abstract][Full Text] [Related]
29. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors.
Murata M
Cancer Sci; 2008 Jul; 99(7):1435-40. PubMed ID: 18452561
[TBL] [Abstract][Full Text] [Related]
30. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism.
Säemann MD; Weichhart T; Zeyda M; Staffler G; Schunn M; Stuhlmeier KM; Sobanov Y; Stulnig TM; Akira S; von Gabain A; von Ahsen U; Hörl WH; Zlabinger GJ
J Clin Invest; 2005 Feb; 115(2):468-75. PubMed ID: 15650774
[TBL] [Abstract][Full Text] [Related]
31. Human lactoferrin activates NF-kappaB through the Toll-like receptor 4 pathway while it interferes with the lipopolysaccharide-stimulated TLR4 signaling.
Ando K; Hasegawa K; Shindo K; Furusawa T; Fujino T; Kikugawa K; Nakano H; Takeuchi O; Akira S; Akiyama T; Gohda J; Inoue J; Hayakawa M
FEBS J; 2010 May; 277(9):2051-66. PubMed ID: 20345905
[TBL] [Abstract][Full Text] [Related]
32. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
33. Identification of a TLR4- and TRIF-dependent activation program of dendritic cells.
Weighardt H; Jusek G; Mages J; Lang R; Hoebe K; Beutler B; Holzmann B
Eur J Immunol; 2004 Feb; 34(2):558-64. PubMed ID: 14768061
[TBL] [Abstract][Full Text] [Related]
34. TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.
Sommariva M; De Cecco L; De Cesare M; Sfondrini L; Ménard S; Melani C; Delia D; Zaffaroni N; Pratesi G; Uva V; Tagliabue E; Balsari A
Cancer Res; 2011 Oct; 71(20):6382-90. PubMed ID: 21878529
[TBL] [Abstract][Full Text] [Related]
35. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.
Michaud M; Martins I; Sukkurwala AQ; Adjemian S; Ma Y; Pellegatti P; Shen S; Kepp O; Scoazec M; Mignot G; Rello-Varona S; Tailler M; Menger L; Vacchelli E; Galluzzi L; Ghiringhelli F; di Virgilio F; Zitvogel L; Kroemer G
Science; 2011 Dec; 334(6062):1573-7. PubMed ID: 22174255
[TBL] [Abstract][Full Text] [Related]
36. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death.
Menger L; Vacchelli E; Adjemian S; Martins I; Ma Y; Shen S; Yamazaki T; Sukkurwala AQ; Michaud M; Mignot G; Schlemmer F; Sulpice E; Locher C; Gidrol X; Ghiringhelli F; Modjtahedi N; Galluzzi L; André F; Zitvogel L; Kepp O; Kroemer G
Sci Transl Med; 2012 Jul; 4(143):143ra99. PubMed ID: 22814852
[TBL] [Abstract][Full Text] [Related]
37. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy.
Hannani D; Sistigu A; Kepp O; Galluzzi L; Kroemer G; Zitvogel L
Cancer J; 2011; 17(5):351-8. PubMed ID: 21952286
[TBL] [Abstract][Full Text] [Related]
38. [Antitumoral immunization during cancer chemotherapy].
Zitvogel L; Hannani D; Aymeric L; Kepp O; Martins I; Kroemer G
Bull Acad Natl Med; 2012 Jun; 196(6):1075-86. PubMed ID: 23596856
[TBL] [Abstract][Full Text] [Related]
39. Toll-like receptor 4 activation in cancer progression and therapy.
Oblak A; Jerala R
Clin Dev Immunol; 2011; 2011():609579. PubMed ID: 22110526
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system.
Ciampricotti M; Hau CS; Doornebal CW; Jonkers J; de Visser KE
Nat Med; 2012 Mar; 18(3):344-6; author reply 346. PubMed ID: 22395693
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
